Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Venetoclax Exposure in AML in Complete Remission
NCT07163793Phase 2Active, not recruiting
- Sponsor
- Northwell Health
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Northwell Health. Started Aug 2025; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07163793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163793.